Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Associated Therapies: -

Clinical Trials

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Phase 4

Conditions: Acute Coronary Syndrome
Chronic Kidney Diseases

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2017-05-12

Last Posted Date: 2018-05-25

Lead Sponsor: North Texas Veterans Healthcare System

Target Recruit Count: 220

Registration Number: NCT03150667

Locations: 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸
VA North Texas Health Care System, Dallas, Texas, United States

TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI

Phase 2

Conditions: ST Elevation Myocardial Infarction

Interventions: Other: Placebo
Drug: Ticagrelor

First Posted Date: 2017-05-09

Last Posted Date: 2017-05-30

Lead Sponsor: Papworth Hospital NHS Foundation Trust

Target Recruit Count: 140

Registration Number: NCT03145194

Locations: 🇬🇧
Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom

ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome

Completed

Conditions: Acute Coronary Syndrome

First Posted Date: 2017-04-26

Last Posted Date: 2023-01-12

Lead Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Target Recruit Count: 480

Registration Number: NCT03129867

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Phase 4

Terminated

Conditions: Coronary Artery Disease
Atherosclerosis
Stents

Interventions: Drug: Clopidogrel
Drug: Ticagrelor
Drug: Aspirin

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 25

Registration Number: NCT03119012

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ticagrelor

First Posted Date: 2017-03-27

Last Posted Date: 2017-03-27

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 51

Registration Number: NCT03092076

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Phase 3

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2017-03-13

Last Posted Date: 2021-08-19

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Registration Number: NCT03078465

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

Phase 2

Conditions: Coronary Artery Disease
Clopidogrel, Poor Metabolism of

Interventions: Drug: ticagrelor
Drug: Clopidogrel

First Posted Date: 2017-02-23

Last Posted Date: 2018-05-07

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 80

Registration Number: NCT03062462

Locations: 🇺🇸
whole blood lumi-aggregometer type 560 VS, Havertown, Pennsylvania, United States

Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor

Phase 2

Completed

Conditions: Adenosine
Coronary Artery Disease
Kidney Dysfunction
Platelet Aggregation
Antiplatelet Therapy

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2017-02-01

Last Posted Date: 2020-04-24

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 90

Registration Number: NCT03039205

Locations: 🇧🇷
Instituto do Coração (InCor) - Hospital das Clínicas da FMUSP, Sao Paulo, Brazil

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Phase 4

Withdrawn

Conditions: Diabetes Mellitus

Interventions: Drug: Ticagrelor
Drug: Prasugrel

First Posted Date: 2017-01-23

Last Posted Date: 2020-07-15

Lead Sponsor: CirQuest Labs, LLC

Registration Number: NCT03027934

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-10-12

Last Posted Date: 2020-12-23

Lead Sponsor: Medical University of Warsaw

Target Recruit Count: 60

Registration Number: NCT02931045

Locations: 🇳🇱
Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam, Amsterdam, Netherlands
🇵🇱
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy